Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- February 2022
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Carcinoma, Non-Small-Cell Lung (MeSH)
- Clinical Decision-Making (MeSH)
- Humans (MeSH)
- Immune Checkpoint Inhibitors (MeSH)
- Lung Neoplasms (MeSH)
- Neoplasm Metastasis (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Future Oncology Journal